Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac037 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Masayoshi Harigai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatosis with Polyangiitis, Microscopic Polyangiitis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
This subgroup analysis of the randomized, double-blind, Phase 3 ADVOCATE study evaluated the efficacy and safety of avacopan compared with tapered prednisone in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Methods
Patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) received either avacopan 30 mg twice daily for 52 weeks plus prednisone-matching placebo or tapered prednisone over 20 weeks plus avacopan-matching placebo for 52 weeks. The two primary efficacy endpoints were clinical remission at Week 26 and sustained remission at Week 52.
Results
Compared with the overall population (N = 330), Japanese patients (N = 21) were older and had worse renal function, and a higher proportion were female and had MPA. The proportion of Japanese patients with clinical remission at Week 26 was 9/11 (81.8%) with avacopan vs. 7/10 (70.0%) with prednisone (overall population: 72.3% vs. 70.1%) and with sustained remission at Week 52 was 8/11 (72.7%) vs. 4/10 (40.0%), respectively (overall population: 65.7% vs. 54.9%). The safety profile of avacopan was similar in Japanese patients and the overall study population.
Conclusions
The efficacy and safety of avacopan in Japanese patients with MPA or GPA were comparable to that observed in the overall ADVOCATE study population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
- Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.
- Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
- Medical Research Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.
- Clinical Projects Management Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.
ORCID-Profile: Naoto Tamura
Zitieren
APA
Harigai, M., Kaname, S., Tamura, N., Dobashi, H., Kubono, S., & Yoshida, T. (2023). Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study. Modern Rheumatology. https://doi.org/10.1093/mr/roac037
Vancouver
Harigai M, Kaname S, Tamura N, Dobashi H, Kubono S, Yoshida T. Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study. Modern Rheumatology. 2023. doi:10.1093/mr/roac037
BibTeX
@article{Harigai2023,
author = {Harigai, Masayoshi and Kaname, Shinya and Tamura, Naoto and Dobashi, Hiroaki and Kubono, Shinichi and Yoshida, Takumitsu},
title = {Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac037}
}
EUVIMED